NCT03394482View on ClinicalTrials.gov

Bioequivalence Study of Lu AF35700

PHASE1CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

January 3, 2018

Primary Completion Date

October 5, 2018

Study Completion Date

October 5, 2018

Conditions
Healthy
Interventions
DRUG

Lu AF35700 5 mg clinical formulation

Lu AF35700 tablets 5 mg oral single dose

DRUG

Lu AF35700 5 mg commercial formulation

Lu AF35700 tablets 5 mg oral single dose

DRUG

Lu AF35700 10 mg clinical formulation

Lu AF35700 tablets 10 mg oral single dose

DRUG

Lu AF35700 10 mg commercial formulation

Lu AF35700 tablets 10 mg oral single dose

DRUG

Lu AF35700 20 mg clinical formulation

Lu AF35700 tablets 20 mg oral single dose

DRUG

Lu AF35700 20 mg commercial formulation

Lu AF35700 tablets 20 mg oral single dose

Trial Locations (1)

Unknown

Covance, Leeds

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT03394482 - Bioequivalence Study of Lu AF35700 | Biotech Hunter | Biotech Hunter